SANTA
CLARA, Calif., Jan. 23,
2025 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq:
SMLR), a pioneer in developing and marketing technology products
and services to healthcare providers to combat chronic diseases,
today announced select preliminary unaudited fourth quarter 2024
financial results and BTC holdings. Semler Scientific will report
full financial results for the fourth quarter and full year ended
December 31, 2024, as well as provide
an update on its Bitcoin holdings after the close of
U.S. financial markets on Tuesday, February
18, 2025.
Select Preliminary Unaudited Fourth Quarter 2024
Results
- Revenues of $12.1 million to
$12.5 million
- Income from operations of $3.4
million to $3.7 million
- Unrealized gain from change in fair value of
bitcoin holdings of approximately $28.9 million
- Cash, restricted cash and cash equivalents at December 31, 2024 of approximately $9.0 million
"We are pleased to report these preliminary unaudited numbers
and significant unrealized gain from our bitcoin
holdings," said Doug
Murphy-Chutorian, M.D., chief executive officer of Semler
Scientific. "We are excited to continue executing on our
bitcoin treasury strategy."
The preliminary unaudited financial information presented in
this press release is based on Semler Scientific's current
expectations and may be adjusted as a result of, among other
things, completion of customary annual audit procedures. It is
possible that the final results may differ from the preliminary
results between now and when results are finalized.
BTC Holdings
As of January 17, 2025, Semler
Scientific held 2,321 bitcoins, which were acquired for an
aggregate purchase price of $191.9
million at an average purchase price of $82,689 per bitcoin, inclusive of
fees and expenses.
Fourth Quarter and Full Year Financial Results Conference
Call
Semler Scientific will report full financial results for the
fourth quarter and full year ended December
31, 2024, as well as provide an update on its
Bitcoin holdings after the close of U.S. financial
markets on Tuesday, February 18,
2025. Dr. Murphy-Chutorian will host a conference call at
4:30 pm ET the same day. Eric Semler, chairman, Renae Cormier, chief financial officer, and
Jennifer Oliva-Herrington, chief
operating officer, will join him on the call.
Please submit questions prior to the start of the call to
ir@semlerscientific.com.
Semler Scientific encourages participants to pre-register for
the conference call using the following link:
https://dpregister.com/sreg/10196221/fe5ab5166e. Callers who
pre-register will be given a conference passcode and unique PIN to
gain immediate access to the call and bypass the live operator.
Participants may pre-register at any time, including up to and
after the call start time.
Those without internet access or unable to pre-register may dial
in by calling:
Domestic callers: 833-816-1161
International callers: 412-317-0717
Please specify to the operator that you would like to join the
"Semler Scientific Call." The conference call will be archived on
Semler Scientific's website at www.semlerscientific.com.
Forward-Looking Statements
This press release contains "forward-looking" statements. Such
statements can be identified by, among other things, the use of
forward-looking language such as the words "believe," "goal,"
"may," "will," "intend," "expect," "anticipate," "estimate,"
"project," "would," "could" or words with similar meaning or the
negatives of these terms or by the discussion of strategy or
intentions. The forward-looking statements in this release include
express or implied statements about Semler Scientific's select
preliminary unaudited fourth quarter 2024 financial results;
acquiring and holding Bitcoin; and its healthcare
business, among others. Such forward-looking statements are subject
to a number of risks and uncertainties that could cause Semler
Scientific's actual results to differ materially from those
discussed here, such as risks related to completion of Semler
Scientific's financial close and/or the annual audit process;
investing in Bitcoin, including Bitcoin's
volatility; implementing a Bitcoin treasury strategy;
along with those other risks related to Bitcoin, its
healthcare business and the other risk factors detailed in Semler
Scientific's filings with the Securities and Exchange Commission.
These forward-looking statements involve assumptions, estimates,
and uncertainties that reflect current internal projections,
expectations or beliefs. There can be no assurance that such
statements will prove to be accurate, and actual results and future
events could differ materially from those anticipated in such
statements. All forward-looking statements contained in this press
release are qualified in their entirety by these cautionary
statements and the risk factors described above. Furthermore, all
such statements are made as of the date of this press release and
Semler Scientific assumes no obligation to update or revise these
statements unless otherwise required by law.
About Semler Scientific, Inc.:
Semler Scientific, Inc. is a pioneer in developing and marketing
technology products and services to healthcare providers to combat
chronic diseases. Its flagship product, QuantaFlo®, which is
patented and cleared by the U.S. Food and Drug Administration
(FDA), is a rapid point-of-care test that measures arterial blood
flow in the extremities. The QuantaFlo test aids in the diagnosis
of cardiovascular diseases, such as peripheral arterial disease
(PAD), and Semler Scientific is seeking a new 510(k) clearance for
expanded indications. QuantaFlo is used by healthcare providers to
evaluate their patient's risk of mortality and major adverse
cardiovascular events (MACE). Semler Scientific also invests in
Bitcoin and has adopted Bitcoin as its
primary treasury asset.
INVESTOR CONTACT:
Renae Cormier
Chief Financial Officer
ir@semlerscientific.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/semler-scientific-announces-select-preliminary-unaudited-fourth-quarter-2024-financial-results-and-significant-unrealized-gain-from-change-in-fair-value-of-bitcoin-holdings-302359078.html
SOURCE Semler Scientific, Inc.
